XORTX Finalized $2.7M Prospectus Supplement and Concurrent Private Placement for the Offering of Units
Author: Charles Gross | March 04, 2024 08:21am
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a second tranche closing (the “Second Tranche Closing”) of gross proceeds of CAD $224,850 under previously announced offering, including CAD $99,000 in a concurrent private placement of the Company in connection with international subscribers.
Posted In: TSXV:XRTX XRTX